Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been assigned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $6.17.

Several equities analysts have recently weighed in on CNTX shares. JMP Securities initiated coverage on Context Therapeutics in a report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price objective for the company. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a research note on Friday. Finally, Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th.

Context Therapeutics Stock Up 0.2 %

NASDAQ:CNTX opened at $0.77 on Monday. Context Therapeutics has a twelve month low of $0.64 and a twelve month high of $2.75. The company has a market cap of $57.88 million, a P/E ratio of -0.85 and a beta of 2.06. The business has a 50 day moving average price of $0.85 and a two-hundred day moving average price of $1.43.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. As a group, analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

A number of hedge funds have recently made changes to their positions in CNTX. Shay Capital LLC acquired a new position in shares of Context Therapeutics during the 4th quarter worth approximately $52,000. MPM Bioimpact LLC acquired a new position in shares of Context Therapeutics in the fourth quarter valued at $15,441,000. Millennium Management LLC raised its position in shares of Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after purchasing an additional 34,835 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth about $31,000. Finally, Allostery Investments LP bought a new stake in shares of Context Therapeutics during the 4th quarter worth about $998,000. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.